| For: | Loo N, Lawitz E, Alkhouri N, Wells J, Landaverde C, Coste A, Salcido R, Scott M, Poordad F. Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients. World J Gastroenterol 2019; 25(18): 2229-2239 [PMID: 31143073 DOI: 10.3748/wjg.v25.i18.2229] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v25/i18/2229.htm |
| Number | Citing Articles |
| 1 |
Semra Karaman Kamalı, Sevtap Senoglu, Sercan Kamalı, Yusuf Emre Ozdemir, Kadriye Kart Yasar. Epidemiological characteristics, genotype patterns, and treatment outcomes in chronic hepatitis C patients receiving direct-acting antivirals: a cohort study from Istanbul, Türkiye. BMC Infectious Diseases 2026; 26(1) doi: 10.1186/s12879-026-12850-5
|
| 2 |
Sergii V. Fedorchenko, Tatiana Martynovych, Zhanna Klimenko, Iryna Solianyk. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first‐ and second‐generation NS5A inhibitors. Journal of Medical Virology 2021; 93(8) doi: 10.1002/jmv.26935
|
| 3 |
Rohit Kumar, Tahir Hussain Wani, Rashid Ali. The Piloty-Robinson Reaction: A Versatile Tool for the Synthesis of 3,4-Disubstituted Pyrroles. Polycyclic Aromatic Compounds 2025; 45(9) doi: 10.1080/10406638.2025.2509695
|
| 4 |
Sumaiah J. Alarfaj, Abdullah Alzahrani, Anfal Alotaibi, Malak Almutairi, Mashael Hakami, Njood Alhomaid, Noori Alharthi, Ghazwa B. Korayem, Abdullah Alghamdi. The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia. Saudi Pharmaceutical Journal 2022; 30(10) doi: 10.1016/j.jsps.2022.07.005
|
| 5 |
Mirinda Ann Gormley, Matthew J Akiyama, Lior Rennert, Kerry A Howard, Brianna L Norton, Irene Pericot-Valverde, Sam Muench, Moonseong Heo, Alain H Litwin. Changes in Health-related Quality of Life for Hepatitis C Virus–Infected People Who Inject Drugs While on Opioid Agonist Treatment Following Sustained Virologic Response. Clinical Infectious Diseases 2022; 74(9) doi: 10.1093/cid/ciab669
|
| 6 |
N. Jeelan Basha, S. M. Basavarajaiah, K. Shyamsunder. Therapeutic potential of pyrrole and pyrrolidine analogs: an update. Molecular Diversity 2022; 26(5) doi: 10.1007/s11030-022-10387-8
|
| 7 |
Xinyao Huang, Yingying Chen, Song Li, Yan Wen, Hao Liu, Gang Cao. Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system. Medicine 2026; 105(16) doi: 10.1097/MD.0000000000048160
|
| 8 |
Ahmet Sahin, Ozlem Akay. Experience with direct-acting antivirals in genotype 1–5 infected chronic hepatitis C patients in Turkey. Annals of Saudi Medicine 2023; 43(5) doi: 10.5144/0256-4947.2023.308
|
| 9 |
Laura Cristina Gómez-Moreno, Samuel David García-Vega, Anlly Paola Pineda-García, María Adelaida Lopera-Baena, Andrés Fernando Rodríguez-Gutiérrez. Antivirales de acción directa contra la hepatitis C: revisión narrativa. Hepatología 2024; 5(2) doi: 10.59093/27112330.109
|
| 10 |
V. T. Ivashkin, V. P. Chulanov, N. A. Mamonova, M. V. Maevskaya, M. S. Zharkova, I. N. Tikhonov, P. O. Bogomolov, E. V. Volchkova, A. S. Dmitriev, O. O. Znojko, E. A. Klimova, K. V. Kozlov, I. E. Kravchenko, E. Yu. Malinnikova, R. V. Maslennikov, M. I. Mikhailov, K. E. Novak, I. G. Nikitin, V. E. Syutkin, E. V. Esaulenko, A. A. Sheptulin, E. N. Shirokova, N. D. Yushchuk. Clinical Practice Guidelines of the Russian Society for the Study of the Liver, the Russian Gastroenterological Association, the National Scientific Society of Infectious Disease Specialists for the Diagnosis and Treatment of Chronic Hepatitis C. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2023; 33(1) doi: 10.22416/1382-4376-2023-33-1-84-124
|
| 11 |
Bernd Schulte, Christiane S Schmidt, Jakob Manthey, Lisa Strada, Stefan Christensen, Konrad Cimander, Herbert Görne, Pavel Khaykin, Norbert Scherbaum, Stefan Walcher, Stefan Mauss, Ingo Schäfer, Uwe Verthein, Jürgen Rehm, Jens Reimer. Clinical and Patient-Reported Outcomes of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C Among Patients on Opioid Agonist Treatment: A Real-world Prospective Cohort Study. Open Forum Infectious Diseases 2020; 7(8) doi: 10.1093/ofid/ofaa317
|